- Asthma & Allergy Foundation of America - https://aafa.org -

Continuing Medical Education (CME) Programs

Posted By Tanya Bumgardner On In | Comments Disabled

Continuing Medical Education (CME) Programs

The Asthma and Allergy Foundation of America (AAFA), in collaboration with PlatformQ Health, offers a variety of free continuing medical education (CME) programs for health care providers. The programs aim to help health care providers learn more about asthma, allergies, atopic diseases, and treatment options. These programs also provide resources for patient and caregiver support. During the programs, expert panelists cover a wide range of topics. For upcoming programs, you can join live or watch on demand later. Sign up for our monthly newsletters [1] and stay updated on upcoming or on-demand programs.
AAFA offers asthma management education for nurses and respiratory therapists through our Asthma Management Education Online (AME-O) course. Learn more about our AME-O course [2] and how to earn 8.75 contact hours.

Upcoming programs

There are no upcoming programs at this time. Be sure to check back soon.

CME Programs on Asthma and Allergy

View our programs on asthma and allergy below. You can earn an AMA PRA Category 1 Credit™, as noted.

Asthma

Applying Guidelines and Latest Evidence to the Management of Moderate‐to‐Severe Asthma in Children and Adults

Topics discussed during this program include:

  • The impact of moderate-to-severe asthma on airway remodeling and lung development in children
  • Conditions that occur frequently with asthma 
  • Strategies to develop personalized asthma treatment plans 

Earn AMA PRA Category 1 Credit™ through July 20, 2024. Watch on demand [3].

[3]

Applying the Latest Guidelines and Recommendations to Initiate Biologic Therapy and Control Moderate-to-Severe Asthma Symptoms

Topics discussed during this program include:

  • The burden of uncontrolled asthma
  • The impact of asthma phenotypes/endotypes and type 2 comorbidities
  • Current data on the efficacy and safety of biologics

Please note the AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube [4]

Biologic Therapy for Patients with Severe Asthma: Impeding the Inflammatory Cascade

Topics discussed during this program include:

  • Roles of various inflammatory pathways in severe asthma
  • Mechanisms of action of various therapies and their safety and efficacy data
  • How a new treatment option targeting TSLP can be integrated into asthma management plan

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube [5]

 

Seeking Control for Moderate-to-Severe Asthma: The Underestimated Impact of Comorbidities Along the Lifespan

Topics discussed during this program include:

  • The effects of comorbid conditions on asthma
  • The evidence behind biologic treatments for asthma
  • Strategies to recognize and better manage moderate-to-severe asthma

Earn AMA PRA Category 1 Credit™ through March 5, 2025. Watch on demand [6].

TARGETING ASTHMA: Community-based Strategies to Enhance Care Access for Children, Adolescents, and Adults – Focus on Social Determinants of Health and Inequities of Care

Topics discussed during this program include:

  • Strategies to enhance access to individualized care among people of racial and ethnic minorities
  • How to identify patients with moderate-to-severe asthma who may benefit from targeted biologic agents
  • How to identify the place of type-2-targeted biologics in the management of moderate-to-severe asthma

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube [7]

Food Allergy

At the Forefront of Food Allergies: Preventive Strategies to Improve Outcomes

Topics discussed during this program include:

  • The changing landscape of food allergy management
  • Newer approaches to enhance food allergen tolerance
  • The key roles of patients and their families when making therapeutic decisions 

Earn AMA PRA Category 1 Credit™ through Sept. 20, 2024. Watch on demand [8].

IgE-targeted Therapies and the Future Management of Food Allergies

Topics discussed during this program include:

  • The diagnostic process for food allergies
  • Emerging biologics targeting IgE
  • The role of shared decision-making in food allergy management

Earn AMA PRA Category 1 Credit™ through Feb. 29, 2025. Watch on demand [9].

 

CME Programs on Allergic Conditions

View our programs on allergic conditions such as chronic spontaneous urticaria (CSU), eosinophilic esophagitis (EoE), atopic dermatitis (AD), and more. You can earn an AMA PRA Category 1 Credit™, as noted.

Atopic Dermatitis

Atopic Dermatitis and Its Comorbid Conditions: How Knowing About Them Will Help Guide Your Treatment Decisions

Topics covered during this program include:

  • Current evidence for currently approved agents for the treatment of moderate-to-severe atopic dermatitis (AD)
  • How the presence of comorbidities can influence the treatment of moderate-to-severe AD
  • How to help patients reach long-term control of their disease

Earn AMA PRA Category 1 Credit™ through Oct. 20, 2024. Watch on demand [10].

[10]

Disparity and Equity in Moderate-to-Severe AD Care: Enhancing Access to Multidisciplinary Care for Patients from Diverse Populations

Topics covered during this program include:

  • The impacts that age, race, and ethnicity have on atopic dermatitis (AD)
  • Management of moderate-to-severe atopic dermatitis
  • The unique challenges that people from diverse racial and ethnic group face when attempting to access care

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube [11]

Endophenotypes, Evidence, and Long-Term Outcomes in Moderate-to-Severe Atopic Dermatitis Management: A Decision Library

Topics covered during this program include:

  • Alignment of therapeutic decisions to clinical endophenotypes in patients of different age groups and races
  • Evidence-based treatment recommendations to achieve long-term disease control
  • Strategies to encourage shared-decision-making with patients

Please note AMA PRA Category 1 Credit™ is no longer available. There are four modules in this program.

Module 1

Watch on YouTube [12]

Module 2

Watch on YouTube [13]

Module 3

Watch on YouTube [14]

Module 4

Watch on YouTube [15]

Eosinophilic Esophagitis

Enhancing Diagnosis and Access to Treatment in EoE: What You Need to Know from Your Patients

Topics discussed during this program include:

  • Guidance on EoE diagnosis
  • The Importance of asking questions to uncover adaptive behaviors
  • Details of the current treatment paradigm

Earn AMA PRA Category 1 Credit™ through September 29, 2024. Watch on demand [16].

[16]

Eosinophilic Esophagitis: Guidelines and Emerging Evidence for Effective Management Strategies

Topics discussed during this program include:

  • How to recognize the symptoms of eosinophilic esophagitis (EoE) across a variety of patient ages to facilitate an early diagnosis
  • Emerging data on new, more efficient, targeted agents for the management of EoE

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube [17]

Nasal Polyps

Caring for Patients with Nasal Polyps in 2023: When to Consider a Biologic or Surgery?

Topics covered during this program include:

  • The latest understanding of chronic rhinosinusitis with nasal polyps (CRSwNP), or nasal polyps
  • People at high risk for recurrence of nasal polyps
  • Treatment options for people with nasal polyps

Earn AMA PRA Category 1 Credit™ through Oct. 12, 2024. Watch on demand [18].

[18]

Cases in Practice: Applying Proposed Care Pathways for Interdisciplinary Collaboration to the Management of Nasal Polyps

Topics covered during this program include:

  • Cases illustrating the adoption of biologics as a therapeutic option for nasal polyps  
  • The underlying pathophysiology of nasal polyps driven by type 2 inflammation 
  • Strategies for implementing interdisciplinary collaborative care 

Earn AMA PRA Category 1 Credit™ through Nov. 2, 2024. Watch on demand [19].

[19]

Diagnostic Workup of the Patient with Uncontrolled Severe Nasal Polyps: Proposed Pathway to Determine Candidacy for Biologic Therapy

Topics covered during this program include:

  • Patient factors to predict relapse risk and determine candidacy for biologics
  • Emerging models for interdisciplinary collaboration in the care of people with nasal polyps

Earn AMA PRA Category 1 Credit™ through Nov. 14, 2024. Watch on demand [20].

[20]

 

Moving Toward a Targeted Approach for Nasal Polyps

Topics discussed during this course include:

  • The patient burden of nasal polyps
  • Limitations of traditional nasal polyp treatments and emerging therapies for those with nasal polyps
  • Rationale for targeted approaches to nasal polyp management

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube [21]

Multidisciplinary Approach to the Management of CRS with Refractory Nasal Polyps: ENT, Allergist, and Patient Partnerships to Enhance Care and QoL

Topics discussed during this program include:

  • Patient-centered treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Disease burden
  • The impacts that biologics and surgery have on symptoms and quality of life (QoL)

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube [22]

Surgery or Biologic for Nasal Polyps? A Close Look at the Evidence

Topics discussed during this program include:

  • The underlying pathways that lead to nasal polyps and drive recurrent disease and treatment resistance
  • The burdens faced by patients with nasal polyps
  • Evidence supporting the efficacy and safety of biologic agents for the treatment of nasal polyps

Earn AMA PRA Category 1 Credit™ through Oct. 12, 2024. Watch on demand [23].

[23]

Urticaria

The Increasing Importance of Identifying Urticaria Subtypes to Achieve Control: Opportunities with T2 Inflammation Targeting Agents

Topics discussed during this program include:

  • The relationships between chronic inducible urticaria (CIndU) triggers and underlying pathophysiologic pathways
  • How to optimize treatment of chronic spontaneous urticaria (CSU) and CIndU
  • Strategies to identify urticaria subtypes

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube [24]

Chronic Spontaneous Urticaria: New Hope with Emerging Targeted Agents

Topics discussed during this program include:

  • The latest in chronic spontaneous urticaria (CSU) treatment options
  • Management and treatment escalation standards
  • Perspectives from the patient journey

Please note AMA PRA Category 1 Credit™ is no longer available.

Watch on YouTube [25]

[26]
EDUCATION PROGRAMS [27]

Support Our Work

Over the past 15 years, there have been moderate advances in U.S. public policy, health care and research, but racial gaps in asthma outcomes have not changed. Minority groups continue to bear disproportionate hardship in managing asthma.

Donate Today > [28]

Related Content

Chick-fil-A product change alert

AAFA Expands HEAL Program to Further Serve Communities Facing Health Inequities [29]

Lunch Box hacks

A New Free Online Class Can Improve Your Asthma Health [30]

Milk Allergy Alert

AAFA Receives CDC Funding Award to Improve Asthma Care and Outcomes for At-Risk Populations [31]

View more blog articles > [32]